Ilumink, a fresh spin-out of the University of Cambridge, is building links with industry and raising seed financing to commercialise technology which aims to disrupt the counterfeit drug black market. The company is developing liquid crystal lasers, spun out from the university’s engineering department and funded by the Royal Academy of Engineering, which can be…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
